Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations

被引：8
|
作者：
Claudiani, Simone [1 ,2 ]
Apperley, Jane F. [1 ,2 ]
Khan, Afzal [2 ]
Khorashad, Jamshid [2 ]
Milojkovic, Dragana [1 ]
机构：
[1] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Dept Haematol, London, England
[2] Imperial Coll London, Hammersmith Hosp, Dept Immun & Inflammat, Ctr Haematol,Fac Med, London, England
来源：
HAEMATOLOGICA | 2020年 / 105卷 / 05期
关键词：
MOLECULAR RESPONSE; CLINICAL-PRACTICE; INHIBITORS; IMATINIB; DISCONTINUATION; RECOMMENDATIONS; GUIDELINES; DASATINIB;
D O I：
10.3324/haematol.2019.234179
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E225 / E227
页数：3
相关论文
共 50 条
  • [21] Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
    Takeuchi, Asako
    Kondo, Toshinori
    Tasaka, Taizo
    Yamada, Seiko
    Hirose, Tadashi
    Fukuda, Hirofumi
    Shimizu, Risa
    Matsuhashi, Yoshiko
    Kondo, Eisei
    Wada, Hideho
    LEUKEMIA RESEARCH REPORTS, 2021, 15
  • [22] Chronic Myeloid Leukemia: Beyond BCR-ABL1
    Ting Zhou
    L. Jeffrey Medeiros
    Shimin Hu
    Current Hematologic Malignancy Reports, 2018, 13 : 435 - 445
  • [23] Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib
    Chahardouli, Bahram
    Zaker, Farhad
    Mousavi, Seied Asadollah
    Saffari, Zeinab
    Nadali, Fatemeh
    Ostadali, Mohammadreza
    Ghadimi, Habibeh
    Alimoghaddam, Kamran
    Ghavamzade, Ardeshir
    Rostami, Shahrbano
    HEMATOLOGY, 2013, 18 (06) : 327 - 332
  • [24] Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study
    Shih, Ya-Chen Tina
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    LANCET HAEMATOLOGY, 2019, 6 (08): : E398 - E408
  • [25] Treatment-Free Remission in Chronic Myeloid Leukemia
    Molica, Matteo
    Naqvi, Kiran
    Cortes, Jorge E.
    Paul, Shilpa
    Kadia, Tapan M.
    Breccia, Massimo
    Kantarjian, Hagop
    Jabbour, Elias J.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (12) : 686 - 696
  • [26] Treatment-Free Remission in Chronic Myeloid Leukemia
    Bourne, Garrett
    Bhatia, Ravi
    Jamy, Omer
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (09)
  • [27] BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase
    Hwan Kim, Dennis Dong
    Simon Kim, Taehyung
    Atenafu, Eshetu G.
    Novitzky Basso, Igor
    Forrest, Donna
    Bence-Bruckler, Isabelle
    Savoie, Lynn
    Busque, Lambert
    Keating, Mary-Margaret
    Delage, Robert
    Xenocostas, Anargyros
    Liew, Elena
    Paulson, Kristjan
    Stockley, Tracy
    Laneuville, Pierre
    Lipton, Jeffrey H.
    Kamel-Reid, Suzanne
    Leber, Brian
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (01) : 136 - 145
  • [28] Management of Patients with Treatment-Free Remission in Chronic Myeloid Leukemia
    Musteata, Vasile, Sr.
    Pinzari, Stela
    Sghibneva-Bobeico, Nina
    BLOOD, 2022, 140 : 12228 - 12228
  • [29] Role of Treatment in the Appearance and Selection of BCR-ABL1 Kinase Domain Mutations
    Filip Razga
    Tomas Jurcek
    Daniela Zackova
    Dana Dvorakova
    Martina Toskova
    Ivana Jeziskova
    Jiri Mayer
    Zdenek Racil
    Molecular Diagnosis & Therapy, 2012, 16 : 251 - 259
  • [30] IMPACT OF TREATMENT ADMINISTRATION ON SELECTION OF BCR-ABL1 KINASE DOMAIN MUTATIONS
    Razga, F.
    Jurcek, T.
    Zackova, D.
    Dvorakova, D.
    Toskova, M.
    Jeziskova, I.
    Mayer, J.
    Racil, Z.
    HAEMATOLOGICA, 2012, 97 : 536 - 537
12345